grade II glioma

Summary

grade II glioma (MONDO:0021639) is a cancer (an umbrella term covering 5 Mondo subtypes) and 11 clinical trials. Top therapeutic interventions include infigratinib, chlorotoxin, and ds-1001b. A subtype of low grade glioma — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

• Classification: Cancer
• Umbrella term: 5 Mondo subtypes
• Clinical trials: 11

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	grade II glioma
Mondo ID	MONDO:0021639
NCIT	C132505
UMLS	C4330050
MedGen	1391502
GARD	0025345
Is cancer (heuristic)	yes

Also known as: grade II glioma · WHO grade II glioma

Disease family

This is a subtype of low grade glioma. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by etiologic mechanism › cancer or benign tumor › neoplastic disease or syndrome › neoplasm › nervous system neoplasm › neuroepithelial neoplasm › glioma › low grade glioma › grade II glioma

Related subtypes (5): schwannoma, angiocentric glioma, low grade astrocytic tumor, childhood low-grade glioma, diffuse low-grade glioma, MAPK pathway–altered

Subtypes (5): diffuse astrocytoma, oligodendroglioma, ependymoma, oligoastrocytoma, chordoid glioma of the third ventricle

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 11.

Phase distribution (across all retrieved trials)

Phase	Trials
PHASE1	4
PHASE1/PHASE2	2
PHASE2	2
Not specified	2
EARLY_PHASE1	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT04458272	PHASE2	ACTIVE_NOT_RECRUITING	A Study of DS-1001b in Patients With Chemotherapy- and Radiotherapy-Naive IDH1 Mutated WHO Grade II Glioma
NCT04623931	PHASE2	RECRUITING	Chemotherapy and Radiation Therapy for the Treatment of IDH Wildtype Gliomas or Non-histological (Molecular) Glioblastomas
NCT03914742	PHASE1/PHASE2	COMPLETED	BGB-290 and Temozolomide in Treating Patients With Recurrent Gliomas With IDH1/2 Mutations
NCT05222165	PHASE1/PHASE2	WITHDRAWN	Study With Infigratinib in Subjects With Advanced Solid and CNS Tumors or Recurrent or Progressive Low-Grade Glioma With Selected FGFR1-3 Alterations
NCT02208362	PHASE1	ACTIVE_NOT_RECRUITING	Genetically Modified T-cells in Treating Patients With Recurrent or Refractory Malignant Glioma
NCT03749187	PHASE1	ACTIVE_NOT_RECRUITING	BGB-290 and Temozolomide in Treating Isocitrate Dehydrogenase (IDH)1/2-Mutant Grade I-IV Gliomas
NCT04214392	PHASE1	ACTIVE_NOT_RECRUITING	Chimeric Antigen Receptor (CAR) T Cells With a Chlorotoxin Tumor-Targeting Domain for the Treatment of MMP2+ Recurrent or Progressive Glioblastoma
NCT04540107	PHASE1	RECRUITING	Serial MR Imaging and MR Spectroscopic Imaging for the Characterization of Lower Grade Glioma
NCT04135807	EARLY_PHASE1	RECRUITING	Implantable Microdevice In Primary Brain Tumors
NCT03251027	Not specified	ACTIVE_NOT_RECRUITING	Intensity-Modulated Stereotactic Radiation Therapy in Treating Patients With Grade II-IV Glioma
NCT04479696	Not specified	RECRUITING	Customized Neuro-Imaging Referenced Symptom Video for the Reduction of Patient and Caregiver Anxiety Around Radiation Treatment for Brain Tumors

Drugs tested across these trials (top 30)

Molecule	Max phase	Trials referencing
INFIGRATINIB	4	1
CHLOROTOXIN	2	1
DS-1001B	2	1
CHEMBL4228794	0	3